BIOMAT Database Logo BIOMAT Database Logo

Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis. 1989

M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi

The synthesis of the stereoisomeric 1,2-bis(3-hydroxyphenyl)ethylenediamines (1-4) from meso-1,2-bis(2-hydroxyphenyl)ethylenediamine and 3-methoxybenzaldehyde by a diaza-Cope-rearrangement and subsequent ether cleavage with BBr3 and their conversion into the [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-complexes with K2PtCl4 (1-PtCl2 - 4-PtCl2) is described.

UI MeSH Term Description Entries
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer

Related Publications

M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
February 1990, Archiv der Pharmazie,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
February 1992, Archiv der Pharmazie,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
February 1991, Archiv der Pharmazie,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
January 1990, Journal of cancer research and clinical oncology,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
[The antineoplastic action of o-substituted [1,2-bis(4-hydroxyphenyl)-ethylenediamine]dichloroplatinum (II) complexes and their methylethers].
July 1988, Archiv der Pharmazie,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
May 1995, Archiv der Pharmazie,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
May 1990, Archiv der Pharmazie,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
January 1992, Journal of cancer research and clinical oncology,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
October 1981, Journal of medicinal chemistry,
M Jennerwein, and R Gust, and R Müller, and H Schönenberger, and J Engel, and M R Berger, and D Schmähl, and S Seeber, and R Osieka, and G Atassi
[N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
November 2005, Journal of medicinal chemistry,
Copied contents to your clipboard!